Add to ORKGMAJORITY of early-stage breast cancers express estrogen receptors (ER) and receive tamoxifenin the adjuvant setting. Yet up to 40 % of these patients will relapse on tamoxifen and develop incurable metastatic disease. Recent evidence from large randomised controlled trials exploring the role of aromatase inhibitors (AI) in the adjuvant setting shows a benefit from the novel strategy, how-ever, the optimal sequence and duration of AI/Tamoxifen treatment is unknown. Therefore, it is vita
Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a common o...
Although endocrine treatment of breast cancer is effective and common practice, in advanced disease ...
Despite recent advances in diagnosis, classification, and therapeutic management, breast cancer (BC)...
MAJORITY of early-stage breast cancers express estrogen receptors (ER) and receive tamoxifenin the a...
Carmen Criscitiello1, Debora Fumagalli1, Kamal S Saini2, Sherene Loi11Breast Cancer Translational Re...
Tamoxifen was the first targeted anticancer agent for breast cancer patients and its effects on redu...
BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major...
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
<div><p>Aromatase inhibitors (AIs) are the most effective class of drugs in the endocrine treatment ...
Purpose We have previously identified a set of breast cancer antiestrogen resistance (BCAR) genes ca...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
Endocrine treatment has had a groundbreaking contribution to the decline in breast cancer mortality....
Aromatase inhibitors (AIs) are the most effective class of drugs in the endocrine treatment of breas...
<div><p>Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a ...
Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a common o...
Although endocrine treatment of breast cancer is effective and common practice, in advanced disease ...
Despite recent advances in diagnosis, classification, and therapeutic management, breast cancer (BC)...
MAJORITY of early-stage breast cancers express estrogen receptors (ER) and receive tamoxifenin the a...
Carmen Criscitiello1, Debora Fumagalli1, Kamal S Saini2, Sherene Loi11Breast Cancer Translational Re...
Tamoxifen was the first targeted anticancer agent for breast cancer patients and its effects on redu...
BACKGROUND: Endocrine therapy reduces breast cancer mortality by 40%, but resistance remains a major...
Breast cancer is the most frequent malignancy diagnosed in women. Approximately 70% of breast tumors...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
<div><p>Aromatase inhibitors (AIs) are the most effective class of drugs in the endocrine treatment ...
Purpose We have previously identified a set of breast cancer antiestrogen resistance (BCAR) genes ca...
17β-Estradiol (E2) plays a pivotal role in the development and progression of breast cancer. As a re...
Endocrine treatment has had a groundbreaking contribution to the decline in breast cancer mortality....
Aromatase inhibitors (AIs) are the most effective class of drugs in the endocrine treatment of breas...
<div><p>Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a ...
Resistance to tamoxifen (Tam), a widely used antagonist of the estrogen receptor (ER), is a common o...
Although endocrine treatment of breast cancer is effective and common practice, in advanced disease ...
Despite recent advances in diagnosis, classification, and therapeutic management, breast cancer (BC)...